In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Maria Bitar und 4 weiteren Autor:innen. Beteiligte Einrichtung: INSERM ERL 1336, UMRS 8228, Sorbonne Université-ENS-PSL-CNRS, Paris F-75006, France. Hauptthemen laut MEDLINE: Imipenem, Mycobacterium abscessus, Anti-Bacterial Agents, Azabicyclo Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Vaincre la Mucoviscidose, l'Association Grégory Lemarchal, l’Association Grégory Lemarchal.
Abstract (Originalsprache)
Objectives
Mycobacterium abscessus is the most frequent of the rapidly growing mycobacteria responsible for lung infections in patients suffering from cystic fibrosis and COPD. Imipenem is currently recommended in the treatment of these infections in spite of β-lactamase production. Since the targets of β-lactams include transpeptidases of both the l,d and d,d specificities, we tested, in vitro, intracellularly and in vivo, a combination of two β-lactams active on these enzymes, amoxicillin and imipenem, alone or in combination with the β-lactamase inhibitor relebactam.
Methods
Drug combinations were evaluated against M. abscessus CIP 104536T and clinical isolates (n = 35) by determining MICs, FIC indices and time–killing. Drug combinations were also evaluated in macrophages and in mice.
Results
In the presence of relebactam, synergy between amoxicillin and imipenem was observed against both M. abscessus CIP 104536T and the clinical isolates. Against M. abscessus CIP 104536T, the addition of 1 mg/L imipenem and 4 mg/L relebactam led to a decrease in the MIC of amoxicillin from 64 to 1 mg/L. The triple combination was active in vitro and intracellularly (a 4.30 decrease in the log10 cfu/mL and 82% killing, respectively). The triple combination was effective in reducing log10 cfu in mouse organs and mouse spleen weights, and in preventing losses in mouse weights.
Conclusions
The amoxicillin/imipenem/relebactam combination was synergistic in vitro and effective in vivo against M. abscessus. Since these drugs are clinically available, the triple combination should be considered by clinicians and further evaluated based on the reporting of the patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- INSERM ERL 1336, UMRS 8228, Sorbonne Université-ENS-PSL-CNRS, Paris F-75006, France.
- Inserm, Université Paris-Saclay, UVSQ, Infection et inflammation, Montigny-Le-Bretonneux F-78180, France.
- Assistance Publique-Hôpitaux de Paris, GHU Paris-Saclay, Service de Microbiologie, Hôpital Raymond Poincaré, Garches F-92380, France.
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Université Paris Cité, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris F-75015, France.
ORCID-Profile: Michel Arthur
Förderung
- Vaincre la Mucoviscidose
- l'Association Grégory Lemarchal
- l’Association Grégory Lemarchal
Zitieren
APA
Bitar, M., Le Moigne, V., Herrmann, J. L., Arthur, M., & Mainardi, J. L. (2025). In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf101
Vancouver
Bitar M, Le Moigne V, Herrmann JL, Arthur M, Mainardi JL. In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf101
BibTeX
@article{Bitar2025,
author = {Bitar, Maria and Le Moigne, Vincent and Herrmann, Jean-Louis and Arthur, Michel and Mainardi, Jean-Luc},
title = {In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf101}
}
EUVIMED